The boss of Ozempic maker Novo Nordisk lost his job yesterday after its share price plunged amid intensifying competition in ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...

Over Lars Fruergaard Jørgensen's eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company ...

U.S.-listed shares of Novo Nordisk declined in the opening minutes of trading Friday on the surprise news that CEO Lars ...

Healthcare professionals who "do exceptional things" and "refuse to accept medicine as it is." Those who are "unsatisfied, ...

Eli Lilly and Company ( NYSE: LLY) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET Lucas Montarce - CFO Mike Czapar - SVP, IR ...

Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

Eli Lilly is pumping iron in the GLP-1 prescription ring, gaining muscle with a 52.4% market share and a beefy $1,100 target.